List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6504856/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MSâ€based glycomics and glycoproteomics methods enabling isomeric characterization. Mass Spectrometry Reviews, 2023, 42, 577-616.	5.4	40
2	<scp>ENIGMA</scp> brain injury: Framework, challenges, and opportunities. Human Brain Mapping, 2022, 43, 149-166.	3.6	33
3	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. Journal of Neurology, 2022, 269, 2080-2098.	3.6	21
4	Microvascular imaging ultrasound (MicroV) and power Doppler vascularization analysis in a pediatric population with early scrotal pain onset. Japanese Journal of Radiology, 2022, 40, 192-201.	2.4	5
5	Neurological and Neuropsychological Changes Associated with SARS-CoV-2 Infection: New Observations, New Mechanisms. Neuroscientist, 2022, 28, 552-571.	3.5	28
6	Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer's Disease Patients. Cells, 2022, 11, 163.	4.1	7
7	Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices. European Journal of Public Health, 2022, 32, 289-296.	0.3	8
8	The effect of clopidogrel and aspirin on the severity of traumatic brain injury in a rat model. Neurochemistry International, 2022, 154, 105301.	3.8	1
9	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health, The, 2022, 7, e105-e125.	10.0	1,199
10	Mitoquinone supplementation alleviates oxidative stress and pathologic outcomes following repetitive mild traumatic brain injury at a chronic time point. Experimental Neurology, 2022, 351, 113987.	4.1	10
11	Glycomic and Glycoproteomic Techniques in Neurodegenerative Disorders and Neurotrauma: Towards Personalized Markers. Cells, 2022, 11, 581.	4.1	13
12	Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019. The Lancet Child and Adolescent Health, 2022, 6, 367-383.	5.6	48
13	GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask. Frontiers in Neurology, 2022, 13, 835597.	2.4	25
14	Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy. Acta Neuropathologica Communications, 2022, 10, 48.	5.2	11
15	Blood Biomarkers and Structural Imaging Correlations Post-Traumatic Brain Injury: A Systematic Review. Neurosurgery, 2022, 90, 170-179.	1.1	12
16	Brain injury biomarkers: Proteins and autoantibodies interplay. , 2022, , 239-250.		0
17	H1299R Variant in Factor V and Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis Protocol. Genes, 2022, 13, 1019.	2.4	6
18	Cerebrospinal fluid biomarkers of white matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative cervical spondylotic myelopathy. Spine Journal, 2022, 22, 1848-1856.	1.3	1

STEFANIA MONDELLO

#	Article	IF	CITATIONS
19	Exploring serum glycome patterns after moderate to severe traumatic brain injury: A prospective pilot study. EClinicalMedicine, 2022, 50, 101494.	7.1	18
20	Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury. Neuroscientist, 2021, 27, 620-649.	3.5	10
21	Biomarkers for Traumatic Brain Injury: Data Standards and Statistical Considerations. Journal of Neurotrauma, 2021, 38, 2514-2529.	3.4	23
22	Blood-Based Protein Biomarkers for the Management of Traumatic Brain Injuries in Adults Presenting to Emergency Departments with Mild Brain Injury: A Living Systematic Review and Meta-Analysis. Journal of Neurotrauma, 2021, 38, 1086-1106.	3.4	104
23	Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2021, 38, 628-645.	3.4	20
24	Toward a global and reproducible science for brain imaging in neurotrauma: the ENIGMA adult moderate/severe traumatic brain injury working group. Brain Imaging and Behavior, 2021, 15, 526-554.	2.1	16
25	Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12200.	3.7	53
26	Hormones in experimental autoimmune encephalomyelitis (EAE) animal models. Translational Neuroscience, 2021, 12, 164-189.	1.4	6
27	Characterization of Traumatic Brain Injury Research in the Middle East and North Africa Region: A Systematic Review. Neuroepidemiology, 2021, 55, 20-31.	2.3	10
28	Abstract P88: Risk of Stroke in Hospitalized SARS-Cov-2 Infected Patients a Multinational Population-Based Study. Stroke, 2021, 52, .	2.0	4
29	Abstract P81: SARS-CoV-2 and Stroke Characteristics a Report From the Multinational COVID-19 Stroke Study Group. Stroke, 2021, 52, .	2.0	7
30	Perceived Stress in a Gender Perspective: A Survey in a Population of Unemployed Subjects of Southern Italy. Frontiers in Public Health, 2021, 9, 640454.	2.7	30
31	SARS-CoV-2 and Stroke Characteristics. Stroke, 2021, 52, e117-e130.	2.0	51
32	Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Current Medicinal Chemistry, 2021, 28, 2369-2391.	2.4	15
33	Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis. Nature and Science of Sleep, 2021, Volume 13, 873-883.	2.7	9
34	Beirut Ammonium Nitrate Blast: Analysis, Review, and Recommendations. Frontiers in Public Health, 2021, 9, 657996.	2.7	29
35	Effects of sport-related repetitive subconcussive head impacts on biofluid markers: a scoping review protocol. BMJ Open, 2021, 11, e046452.	1.9	6
36	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 870-905.	13.7	229

#	Article	IF	CITATIONS
37	Kollidon VA64 Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2021, 38, 2454-2472.	3.4	5
38	The Burden of Dementia due to Down Syndrome, Parkinson's Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019. Neuroepidemiology, 2021, 55, 286-296.	2.3	24
39	Sleep After Traumatic Brain Injury. , 2021, , 255-268.		Ο
40	Clinical usefulness of anti-muscarinic type 3 receptor autoantibodies in patients with primary SJögren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 795-803.	0.8	1
41	Blood-based traumatic brain injury biomarkers – Clinical utilities and regulatory pathways in the United States, Europe and Canada. Expert Review of Molecular Diagnostics, 2021, 21, 1303-1321.	3.1	19
42	Exploring the evidence for the effectiveness of health interventions for COVID-19 targeting migrants: a systematic review protocol. BMJ Open, 2021, 11, e057985.	1.9	0
43	Family, lifestyles and new and old type of smoking in young adults: insights from an italian multiple-center study. Annali Di Igiene: Medicina Preventiva E Di Comunita, 2021, 33, 131-140.	0.7	2
44	Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone. Antioxidants, 2020, 9, 943.	5.1	67
45	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	13.7	7,664
46	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
47	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	13.7	890
48	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
49	Characteristics and Impact of U.S. Military Blast-Related Mild Traumatic Brain Injury: A Systematic Review. Frontiers in Neurology, 2020, 11, 559318.	2.4	56
50	Advances in Cardiovascular Biomarker Discovery. Biomedicines, 2020, 8, 552.	3.2	31
51	Circulating GFAP and Iba-1 levels are associated with pathophysiological sequelae in the thalamus in a pig model of mild TBI. Scientific Reports, 2020, 10, 13369.	3.3	32
52	Sex Differences in Circulating T-Tau Trajectories After Sports-Concussion and Correlation With Outcome. Frontiers in Neurology, 2020, 11, 651.	2.4	16
53	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330
54	Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study. EBioMedicine, 2020, 59, 102939.	6.1	82

#	Article	IF	CITATIONS
55	Serum Glycomics Profiling of Patients with Primary Restless Legs Syndrome Using LC–MS/MS. Journal of Proteome Research, 2020, 19, 2933-2941.	3.7	10
56	Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study. EBioMedicine, 2020, 56, 102785.	6.1	147
57	Sexâ€Related Differences in the Effects of Sportsâ€Related Concussion: A Review. Journal of Neuroimaging, 2020, 30, 387-409.	2.0	48
58	Night shift work in resident physicians: does it affect mood states and cognitive levels?. Journal of Affective Disorders, 2020, 272, 289-294.	4.1	23
59	Cerebrospinal fluid levels of GFAP and pNF-H are elevated in patients with chronic spinal cord injury and neurological deterioration. Acta Neurochirurgica, 2020, 162, 2075-2086.	1.7	11
60	Editorial: Biomarkers in Neurology. Frontiers in Neurology, 2020, 11, 190.	2.4	6
61	Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets. Molecular Neurobiology, 2020, 57, 2702-2726.	4.0	12
62	Circulating Brain Injury Exosomal Proteins following Moderate-to-Severe Traumatic Brain Injury: Temporal Profile, Outcome Prediction and Therapy Implications. Cells, 2020, 9, 977.	4.1	48
63	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
64	Operation Brain Trauma Therapy: An Exploratory Study of Levetiracetam Treatment Following Mild Traumatic Brain Injury in the Micro Pig. Frontiers in Neurology, 2020, 11, 586958.	2.4	9
65	Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis. Journal of Investigative Medicine, 2020, 68, 1379-1385.	1.6	10
66	Fast Magnetic Resonance Enterography Protocol for the Evaluation of Patients with Crohn's Disease: A Pilot Study. Journal of Clinical Imaging Science, 2020, 10, 25.	1.1	10
67	Serum-Based Phospho-Neurofilament-Heavy Protein as Theranostic Biomarker in Three Models of Traumatic Brain Injury: An Operation Brain Trauma Therapy Study. Journal of Neurotrauma, 2019, 36, 348-359.	3.4	26
68	Rodent Models of Methamphetamine Misuse: Mechanisms of Methamphetamine Action and Comparison of Different Rodent Paradigms. Methods in Molecular Biology, 2019, 2011, 221-250.	0.9	1
69	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
70	Melatonin Therapy Modulates Cerebral Metabolism and Enhances Remyelination by Increasing PDK4 in a Mouse Model of Multiple Sclerosis. Frontiers in Pharmacology, 2019, 10, 147.	3.5	34
71	Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017. Lancet Public Health, The, 2019, 4, e645-e657	10.0	54
72	Editorial: Developing Successful Neuroprotective Treatments for TBI: Translational Approaches, Novel Directions, Opportunities and Challenges. Frontiers in Neurology, 2019, 10, 1326.	2.4	5

#	Article	IF	CITATIONS
73	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 88-106.	10.2	1,512
74	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
75	Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. International Journal of Stroke, 2019, 14, 390-399.	5.9	31
76	Combination of drug and stem cells neurotherapy: Potential interventions in neurotrauma and traumatic brain injury. Neuropharmacology, 2019, 145, 177-198.	4.1	36
77	Extracellular vesicles: pathogenetic, diagnostic and therapeutic value in traumatic brain injury. Expert Review of Proteomics, 2018, 15, 451-461.	3.0	34
78	Operation Brain Trauma Therapy: 2016 Update. Military Medicine, 2018, 183, 303-312.	0.8	41
79	Delayed sleep phase syndrome and bipolar disorder: Pathogenesis and available common biomarkers. Sleep Medicine Reviews, 2018, 41, 133-140.	8.5	23
80	Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms. Progress in Neurobiology, 2018, 165-167, 26-50.	5.7	65
81	Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial. Critical Care Medicine, 2018, 46, 554-561.	0.9	24
82	Subdural hematoma decompression model: A model of traumatic brain injury with ischemic-reperfusional pathophysiology: A review of the literature. Behavioural Brain Research, 2018, 340, 23-28.	2.2	23
83	Psoriasis and Cardiovascular Risk: Correlation Between Psoriasis and Cardiovascular Functional Indices. Angiology, 2018, 69, 31-37.	1.8	38
84	Effects of shortâ€ŧoâ€long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathology and Applied Neurobiology, 2018, 44, 449-462.	3.2	23
85	Docosahexaenoic acid (DHA) enhances the therapeutic potential of neonatal neural stem cell transplantation post—Traumatic brain injury. Behavioural Brain Research, 2018, 340, 1-13.	2.2	27
86	Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onset Pompe Disease (LOPD). Frontiers in Neurology, 2018, 9, 880.	2.4	7
87	Novel biomarker signatures for idiopathic REM sleep behavior disorder. Neurology, 2018, 91, e1710-e1715.	1.1	26
88	Quantitative pupillometry and neuron-specific enolase independently predict return of spontaneous circulation following cardiogenic out-of-hospital cardiac arrest: a prospective pilot study. Scientific Reports, 2018, 8, 15964.	3.3	12
89	Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI. Neurology, 2018, 91, e1385-e1389.	1.1	110
90	LC–MS/MS glycomics of idiopathic rapid eye movement sleep behavior disorder. Electrophoresis, 2018, 39, 3096-3103.	2.4	17

#	Article	IF	CITATIONS
91	Pre-Clinical Testing of Therapies for Traumatic Brain Injury. Journal of Neurotrauma, 2018, 35, 2737-2754.	3.4	68
92	The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. PLoS ONE, 2018, 13, e0198676.	2.5	13
93	Multi-Center Pre-clinical Consortia to Enhance Translation of Therapies and Biomarkers for Traumatic Brain Injury: Operation Brain Trauma Therapy and Beyond. Frontiers in Neurology, 2018, 9, 640.	2.4	42
94	Purkinje cell COX deficiency and mtDNA depletion in an animal model of spinocerebellar ataxia type 1. Journal of Neuroscience Research, 2018, 96, 1576-1585.	2.9	12
95	Biofluid Proteomics and Biomarkers in Traumatic Brain Injury. Methods in Molecular Biology, 2017, 1598, 45-63.	0.9	34
96	Living systematic reviews: 4. Living guideline recommendations. Journal of Clinical Epidemiology, 2017, 91, 47-53.	5.0	184
97	Living systematic review: 1. Introduction—the why, what, when, and how. Journal of Clinical Epidemiology, 2017, 91, 23-30.	5.0	406
98	Living systematic reviews: 2. Combining human and machine effort. Journal of Clinical Epidemiology, 2017, 91, 31-37.	5.0	246
99	Living systematic reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology, 2017, 91, 38-46.	5.0	102
100	New astroglial injury-defined biomarkers for neurotrauma assessment. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3278-3299.	4.3	57
101	Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. Journal of Neurology, 2017, 264, 2472-2480.	3.6	38
102	Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurology, The, 2017, 16, 987-1048.	10.2	1,571
103	Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury. Frontiers in Neurology, 2017, 8, 28.	2.4	113
104	Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review. Frontiers in Neurology, 2017, 8, 300.	2.4	185
105	LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310164.	1.9	50
106	Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments?. Current Oncology, 2016, 23, 165-170.	2.2	8
107	Neuroproteomics and Systems Biology Approach to Identify Temporal Biomarker Changes Post Experimental Traumatic Brain Injury in Rats. Frontiers in Neurology, 2016, 7, 198.	2.4	26
108	A Direct Cortico-Nigral Pathway as Revealed by Constrained Spherical Deconvolution Tractography in Humans. Frontiers in Human Neuroscience, 2016, 10, 374.	2.0	36

#	Article	IF	CITATIONS
109	Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: Comparative analysis of aspirin and clopidogrel treatment. Electrophoresis, 2016, 37, 1562-1576.	2.4	24
110	Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 553-566.	3.4	44
111	Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury. Scientific Reports, 2016, 6, 28203.	3.3	80
112	Exploratory study of serum ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein for outcome prognostication after pediatric cardiac arrest. Resuscitation, 2016, 101, 65-70.	3.0	30
113	Prognostic factors in patients treated with stereotactic image-guided robotic radiosurgery for brain metastases: a single-center retrospective analysis of 223 patients. Neurosurgical Review, 2016, 39, 495-504.	2.4	11
114	Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity. Critical Care, 2016, 20, 285.	5.8	116
115	Role of Systems Biology in Brain Injury Biomarker Discovery: Neuroproteomics Application. Methods in Molecular Biology, 2016, 1462, 157-174.	0.9	9
116	Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients. Scientific Reports, 2016, 6, 24588.	3.3	81
117	Epidemiology and clinical characteristics of traumatic brain injury in Lebanon. Medicine (United) Tj ETQq1 1 0.78	34314 rgB 1.0	T /Qyerlock 1(
118	High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer. Technology in Cancer Research and Treatment, 2016, 15, 179-185.	1.9	21
119	Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 538-552.	3.4	51
120	Nicotinamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 523-537.	3.4	63
121	Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD). Journal of Inherited Metabolic Disease, 2016, 39, 391-398.	3.6	32
122	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
123	Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 567-580.	3.4	40
124	Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 606-614.	3.4	61
125	Insight into Pre-Clinical Models of Traumatic Brain Injury Using Circulating Brain Damage Biomarkers: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 595-605.	3.4	71
126	Levetiracetam Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 581-594.	3.4	60

#	Article	IF	CITATIONS
127	Approach to Modeling, Therapy Evaluation, Drug Selection, and Biomarker Assessments for a Multicenter Pre-Clinical Drug Screening Consortium for Acute Therapies in Severe Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 513-522.	3.4	78
128	Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1030-1044.	1.4	29
129	Data comparison between pharmacological induction of labour and spontaneous delivery. A single centre experience. Ginekologia Polska, 2016, 87, 697-700.	0.7	3
130	8 Years of Experience with Alglucosidase Alpha Treatment: Facts and Perspectives. Journal of Neuromuscular Diseases, 2015, 2, S4-S4.	2.6	0
131	Thyroxine transfer from cerebrospinal fluid into choroid plexus and brain is affected by brefeldin A, low sodium, BCH, and phloretin, in ventriculo-cisternal perfused rabbits. Frontiers in Cell and Developmental Biology, 2015, 3, 60.	3.7	3
132	Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment. PLoS ONE, 2015, 10, e0128601.	2.5	7
133	Acute Temporal Profiles of Serum Levels of UCH-L1 and GFAP and Relationships to Neuronal and Astroglial Pathology following Traumatic Brain Injury in Rats. Journal of Neurotrauma, 2015, 32, 1179-1189.	3.4	55
134	Nanotheragnostic Applications for Ischemic and Hemorrhagic Strokes: Improved Delivery for a Better Prognosis. Current Neurology and Neuroscience Reports, 2015, 15, 505.	4.2	17
135	Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options. Nutrition and Cancer, 2015, 67, 12-26.	2.0	53
136	p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma. Human Pathology, 2015, 46, 231-238.	2.0	23
137	Biomarkers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 127, 245-265.	1.8	25
138	Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. Journal of Neurology, 2015, 262, 968-978.	3.6	61
139	Clinical and pathophysiological clues of respiratory dysfunction in late-onset Pompe disease: New insights from a comparative study by MRI and respiratory function assessment. Neuromuscular Disorders, 2015, 25, 852-858.	0.6	40
140	Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research. Expert Review of Proteomics, 2015, 12, 637-650.	3.0	10
141	Proteomics studies in inner ear disorders: pathophysiology and biomarkers. Expert Review of Proteomics, 2015, 12, 185-196.	3.0	14
142	Developing a molecular taxonomy for traumatic brain injury: a perspective to enable the development of diagnostics and therapeutics. Biomarkers in Medicine, 2015, 9, 619-621.	1.4	4
143	Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions. Molecular Neurobiology, 2015, 52, 696-709.	4.0	56
144	Acute Diagnostic Biomarkers for Spinal Cord Injury: Review of the Literature and Preliminary Research Report. World Neurosurgery, 2015, 83, 867-878.	1.3	91

STEFANIA MONDELLO

#	Article	IF	CITATIONS
145	Minor and Repetitive Head Injury. Advances and Technical Standards in Neurosurgery, 2015, 42, 147-192.	0.5	9
146	Anesthetic Techniques and Cancer Recurrence after Surgery. Scientific World Journal, The, 2014, 2014, 1-10.	2.1	50
147	Complications of Trauma Patients Admitted to the ICU in Level I Academic Trauma Centers in the United States. BioMed Research International, 2014, 2014, 1-7.	1.9	29
148	Brain Injury Markers: Where are We?. Frontiers in Neurology, 2014, 5, 145.	2.4	1
149	Emerging markers of cachexia predict survival in cancer patients. BMC Cancer, 2014, 14, 828.	2.6	44
150	Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?. Alzheimer's Research and Therapy, 2014, 6, 51.	6.2	24
151	A neuroproteomic and systems biology analysis of rat brain post intracerebral hemorrhagic stroke. Brain Research Bulletin, 2014, 102, 46-56.	3.0	30
152	Generalized versus partial reflex seizures: A review. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 512-520.	2.0	70
153	Post-Genomics Nanotechnology Is Gaining Momentum: Nanoproteomics and Applications in Life Sciences. OMICS A Journal of Integrative Biology, 2014, 18, 111-131.	2.0	25
154	Three-dimensional treatment planning for vaginal cuff brachytherapy: Dosimetric effects on organs at risk according to patients position. Brachytherapy, 2014, 13, 568-571.	0.5	13
155	Autoantibodies in traumatic brain injury and central nervous system trauma. Neuroscience, 2014, 281, 16-23.	2.3	32
156	Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 655-662.	2.8	51
157	Ketotifen-induced nocturnal bruxism. European Journal of Pediatrics, 2014, 173, 1585-1586.	2.7	3
158	Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. SpringerPlus, 2014, 3, 123.	1.2	12
159	CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 382-387.	2.2	68
160	The Challenge of Mild Traumatic Brain Injury: Role of Biochemical Markers in Diagnosis of Brain Damage. Medicinal Research Reviews, 2014, 34, 503-531.	10.5	86
161	CSF and Plasma Amyloid-β Temporal Profiles and Relationships with Neurological Status and Mortality after Severe Traumatic Brain Injury. Scientific Reports, 2014, 4, 6446.	3.3	80
162	Bioinformatics Approach to Understanding Interacting Pathways in Neuropsychiatric Disorders. Methods in Molecular Biology, 2014, 1168, 157-172.	0.9	4

#	Article	IF	CITATIONS
163	Human Traumatic Brain Injury Induces Autoantibody Response against Glial Fibrillary Acidic Protein and Its Breakdown Products. PLoS ONE, 2014, 9, e92698.	2.5	149
164	Blood Biomarkers for Acute CNS Insults: Traumatic Brain Injury and Stroke. , 2014, , 303-331.		0
165	Different expression of ubiquitin C-terminal hydrolase-L1 and αll-spectrin in ischemic and hemorrhagic stroke: Potential biomarkers in diagnosis. Brain Research, 2013, 1540, 84-91.	2.2	26
166	Psychogenic Itch Responding to Topiramate. Psychosomatics, 2013, 54, 297-300.	2.5	10
167	An updated overview of animal models in neuropsychiatry. Neuroscience, 2013, 240, 204-218.	2.3	36
168	Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat subdural hematoma decompression model. Journal of Neurosurgery, 2013, 118, 370-380.	1.6	43
169	α-Synuclein in CSF of patients with severe traumatic brain injury. Neurology, 2013, 80, 1662-1668.	1.1	71
170	Assessing neuro-systemic & behavioral components in the pathophysiology of blast-related brain injury. Frontiers in Neurology, 2013, 4, 186.	2.4	59
171	Biomarkers Track Damage after Graded Injury Severity in a Rat Model of Penetrating Brain Injury. Journal of Neurotrauma, 2013, 30, 1161-1169.	3.4	51
172	Preoperative-Induced Mild Hypothermia Attenuates Neuronal Damage in a Rat Subdural Hematoma Model. Acta Neurochirurgica Supplementum, 2013, 118, 77-81.	1.0	9
173	Combining Biochemical and Imaging Markers to Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the Acute Setting: Results from a Pilot Study. PLoS ONE, 2013, 8, e80296.	2.5	79
174	Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum. Journal of Nephrology, 2013, 26, 1151-1159.	2.0	7
175	Glial Neuronal Ratio: A Novel Index for Differentiating Injury Type in Patients with Severe Traumatic Brain Injury. Journal of Neurotrauma, 2012, 29, 1096-1104.	3.4	121
176	Cerebrospinal Fluid Protein Biomarker Panel for Assessment of Neurotoxicity Induced by Kainic Acid in Rats. Toxicological Sciences, 2012, 130, 158-167.	3.1	33
177	The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2012, 6, 235-250.	0.6	3
178	Angiotensin receptor antagonists. Critical Care Medicine, 2012, 40, 1023-1024.	0.9	4
179	Thalamic and Subthalamic Deep Brain Stimulation for Essential Tremor. Neurosurgery, 2012, 70, 840-846.	1.1	264
180	Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. Journal of Trauma, 2012, 72, 1335-1344.	2.3	196

STEFANIA MONDELLO

#	Article	IF	CITATIONS
181	Systems Biology, Bioinformatics, and Biomarkers in Neuropsychiatry. Frontiers in Neuroscience, 2012, 6, 187.	2.8	41
182	Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis, 2012, 33, 3659-3668.	2.4	40
183	Brain Injury Biomarkers May Improve the Predictive Power of the IMPACT Outcome Calculator. Journal of Neurotrauma, 2012, 29, 1770-1778.	3.4	132
184	Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Injury, 2012, 26, 1629-1635.	1.2	53
185	Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurology, 2012, 12, 85.	1.8	56
186	Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention. Annals of Emergency Medicine, 2012, 59, 471-483.	0.6	282
187	Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: A comparison with n-acetylcysteine. European Journal of Pharmacology, 2012, 674, 397-406.	3.5	40
188	Biomarkers in psychiatry: how close are we?. Frontiers in Psychiatry, 2012, 3, 114.	2.6	16
189	Cerebrospinal Fluid Biomarker Candidates for Parkinsonian Disorders. Frontiers in Neurology, 2012, 3, 187.	2.4	28
190	Utilities of TBI Biomarkers in Various Clinical Settings. RSC Drug Discovery Series, 2012, , 184-199.	0.3	0
191	Data Mining Strategies Applied in Brain Injury Models. Springer Optimization and Its Applications, 2012, , 1-13.	0.9	0
192	Genotoxic effects of anesthetic agents: an update. Expert Opinion on Drug Safety, 2011, 10, 891-899.	2.4	27
193	Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Critical Care, 2011, 15, R156.	5.8	181
194	Translating Biomarkers Research to Clinical Care: Applications and Issues for Rehabilomics. PM and R, 2011, 3, S31-8.	1.6	13
195	Glial fibrillary acidic protein: A promising biomarker in pediatric brain injury*. Pediatric Critical Care Medicine, 2011, 12, 603-604.	0.5	13
196	Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice. European Journal of Pharmacology, 2011, 658, 28-40.	3.5	10
197	Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 383, 493-508.	3.0	22
198	Protein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside. Translational Stroke Research, 2011, 2, 455-462.	4.2	25

#	Article	IF	CITATIONS
199	Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient Biofluids. Journal of Neurotrauma, 2011, 28, 861-870.	3.4	205
200	Blood-based diagnostics of traumatic brain injuries. Expert Review of Molecular Diagnostics, 2011, 11, 65-78.	3.1	155
201	Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients. Nutrition, 2010, 26, 677-681.	2.4	23
202	Clutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. European Journal of Pharmacology, 2010, 643, 304-315.	3.5	48
203	Stefania Mondello. Nature, 2010, 466, 1009-1009.	27.8	0
204	αII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients. Journal of Neurotrauma, 2010, 27, 1203-1213.	3.4	193
205	Erythropoietin suppresses peritoneal fibrosis in rat experimental model. European Journal of Pharmacology, 2009, 604, 138-149.	3.5	15
206	Renal Complications in Oncohematologic Patients. Journal of Investigative Medicine, 2009, 57, 892-901.	1.6	6
207	THALIDOMIDE SUPPRESSES SCLEROSING ENCAPSULATING PERITONITIS IN A RAT EXPERIMENTAL MODEL. Shock, 2009, 32, 332-339.	2.1	19
208	Occult hepatitis B virus in liver tissue of individuals without hepatic disease. Journal of Hepatology, 2008, 48, 743-746.	3.7	171
209	Genotoxic effects of anesthetic agents. Expert Opinion on Drug Safety, 2008, 7, 447-458.	2.4	7
210	Hypophosphatemia as Unusual Cause of ARDS in Cushing's Syndrome Secondary to Ectopic CRH Production. A Case Report. Scientific World Journal, The, 2008, 8, 138-144.	2.1	7
211	Risk of Cerebrovascular Events in Hospitalized Patients with SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	1